Ocular Hypertension Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight's, "Ocular Hypertension Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ocular Hypertension pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ocular Hypertension Pipeline Report

* DelveInsight's Ocular Hypertension pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ocular Hypertension treatment.
* The leading Ocular Hypertension Companies working in the market include Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.
* Promising Ocular Hypertension therapies in the various stages of development include AZD4017, DNB-001, AR-12286, SAD448, bimatoprost, bimatoprost/timolol fixed combination, and others.
* March 2024:- Laboratoires Thea- Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan Registered 0.01% in Ocular Hypertensive or Glaucomatous Patients. The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan Registered 0.01% in terms of efficacy.

Request a sample and discover the recent advances in Ocular Hypertension treatment drugs @ Ocular Hypertension Pipeline Outlook Report [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ocular Hypertension Overview

Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease. However, the two are different: ocular hypertension means that the intraocular pressure is high but the optic nerve is not damaged, whereas with glaucoma, the optic nerve has been damaged - and intraocular pressure might be normal or high - which can lead patients to notice a loss of visual field and even central vision in advanced stages of the disorder.

Ocular Hypertension Emerging Drugs Profile

* NCX-470: Nicox
* QLS-101: Qlaris Bio
* TO-O-1001: TheratOcular Biotek Co., Ltd.

Find out more about Ocular Hypertension treatment drugs @ Drugs for Ocular Hypertension Treatment [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ocular Hypertension Therapeutics Assessment

There are approx. 70+ key Ocular Hypertension companies which are developing the therapies for Ocular Hypertension. The Ocular Hypertension companies which have their Ocular Hypertension drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

DelveInsight's Ocular Hypertension pipeline report covers around 75+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Learn more about the emerging Ocular Hypertension pipeline therapies @ Ocular Hypertension Clinical Trials [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Ocular Hypertension Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Ocular Hypertension Companies

Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others.

Dive deep into rich insights for new drugs for Ocular Hypertension Treatment, visit @ Ocular Hypertension Drugs [https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Ocular Hypertension: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ocular Hypertension- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NCX-470: Nicox
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* QLS-101: Qlaris Bio
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* TO-O-1001: TheratOcular Biotek Co., Ltd.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Ocular Hypertension Key Companies
* Ocular Hypertension Key Products
* Ocular Hypertension- Unmet Needs
* Ocular Hypertension- Market Drivers and Barriers
* Ocular Hypertension- Future Perspectives and Conclusion
* Ocular Hypertension Analyst Views
* Ocular Hypertension Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ocular-hypertension-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.